INNO-F1

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Bio & Pharma HK inno.N to release K-CAB in MENA market

South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharm...

Bio & Pharma Boryung, HK inno.N to co-market Kanarb, K-CAB

South Korea’s pharmaceutical companies Boryung Corp. and HK inno.N announced on Wednesday that they will start co-marketing for their respec...

Bio & Pharma HK inno.N reveals differentiated clinical results for K-CAB

South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophag...

Bio & Pharma HK inno.N releases K-Cab in Singapore

South Korean bio-health company HK inno.N announced on Monday that it has released the new drug K-CAB for gastroesophageal reflux disease (GERD) in ...

Bio & Pharma HK inno.N releases new drug for GERD in Indonesia

South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in In...

Travel & Leisure Designer of 2018 Winter Olympic cauldron returns with solo golf cart

Personal space has become more important since the COVID-19 pandemic swept the world, and one South Korean-led industrial design company has develop...

Companies CJ CheilJedang opens internal venture development space Inno Play

South Korea's food and bio giant CJ CheilJedang Corp. on Sunday said it opened Inno Play, an office space for commercializing innovative ideas and d...

Bio & Pharma HK inno.N's GERD drug K-CAB gets approval in Mexico

South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...

Bio & Pharma S.Korea, Japan compete in gastroesophageal reflux drug market

South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical pr...

Bio & Pharma HK inno.N to introduce biosimilars for bone disease treatment from Spain

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...

Bio & Pharma HK inno.N's K-CAB to get insurance benefits in China

South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, ...

Bio & Pharma HK inno.N gets approval to sell K-CAB in Singapore

South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux d...

Bio & Pharma HK inno.N receives sales permit for ulcer treatment in China

HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company an...

Pharmaceuticals HK inno.N’s K-CAB a blockbuster drug with $843 million exports

South Korea’s HK inno.N Corp. has signed a 640 billion won ($540 million) contract to license out its technology for K-CAB, a gastroesophageal...

IPOs HK inno.N’s IPO attracts $25 bn from retail investors

HK inno.N Corp. (inno.N), a pharmaceuticals unit of Kolmar Korea, drew a massive $25 billion from retail investors for its listing thanks to its s...

IPOs HK inno.N’s IPO price set at top end with record demand for Kosdaq listing

HK inno.N Corp. (inno.N), a pharmaceuticals unit of South Korea's Kolmar Korea, set the initial public offering price at the top end of the proposed...

Private equity STIC to cash in on Aug IPOs following HYBE block sale

South Korea's private equity firm STIC Investments Inc. is tipped to be one of the main beneficiaries of upcoming initial public offerings in the co...

IPOs HK inno.N poised to bolster S.Korea's IPO lineup in H2

HK inno.N Corp., a pharmaceuticals unit of South Korea's Kolmar Korea, is set to go public in early August at a valuation of around 2 trillion won (...

IPOs HK inno.N plans 2021 IPO with $1.8 bn valuation

HK inno.N Corp. (inno.N), previously known as CJ Healthcare Co. and now a subsidiary of Kolmar Korea, has initiated the IPO process for listing with...